Skip to main content

Table 3 Correlation analyses between inflammatory and AD CSF biomarkers by diagnostic category

From: Glial activation and inflammation along the Alzheimer’s disease continuum

All symptomatic subjects (SCD, MCI, AD dementia) (n = 85)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
 CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
 CSF T-tau .318, p < .01 .589, p < .001 .276, p < .05 .507, p < .001 .400, p < .001
 CSF P-tau .289, p < .01 .444, p < .001 n.s. .368, p < .001 .290, p < .01
SCD (n = 18)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
 CSF Aβ42 n.s. n.s. n.s. n.s. .568, p < .05
 CSF T-tau .629, p < .01 .730, p < .001 n.s. .616, p < .01 n.s.
 CSF P-tau .655, p < .01 .679, p < .01 n.s. .536, p < .05 n.s.
MCI (n = 40)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
 CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
 CSF T-tau n.s. .409, p < .01 n.s. .479, p < .01 .330, p < .05
 CSF P-tau .335, p < .05 .347, p < .05 n.s. .375, p < .05 .364, p < .05
AD dementia (n = 29)
Variable CSF sTREM2 CSF YKL-40 CSF MCP-1 CSF Fractalkine CSF Clusterin
 CSF Aβ42 n.s. n.s. n.s. n.s. n.s.
 CSF T-tau n.s. .660, p < .001 n.s. .550, p < .01 .415, p < .05
 CSF P-tau n.s. .439, p < .05 n.s. n.s. n.s.
  1. Reported values are Pearson’s r and associated p value
  2. n.s. non-significant (p > .05)